Biocon Biologics, a subsidiary of Biocon, on Monday said it has got a licence from US-based Adagio Therapeutics for an antibody therapy to treat and prevent COVID-19, for India and select markets. Adagio Therapeutics has granted an exclusive licence to the company to manufacture and commercialise an antibody treatment based on ADG20 for India and select emerging markets, Biocon Biologics …
